DaVita Inc. Form 8-K Summary
Business Context and Reporting Period
DaVita Inc. (DVA) filed this Current Report on Form 8-K on November 5, 2019. The filing primarily serves to announce the Company's financial results for the three and nine months ended September 30, 2019, and to disclose a significant change in Board composition.
Key Financial Metrics
This 8-K filing references a press release (Exhibit 99.1) containing the detailed financial results for the periods ended September 30, 2019. The text of this specific filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these metrics.
Material Changes and Corporate Events
- Board Departure: Peter Grauer, a Board member since 1994 and lead independent director since 2003, notified the Board of his intention to retire. He will not stand for re-election at the 2020 Annual Meeting of Stockholders.
- Reasoning: Mr. Grauer cited the completion of the Chief Executive Officer transition (effective June 1, 2019) and the sale of the DaVita Medical Group division (completed June 19, 2019) as appropriate timing for his retirement.
- Transition: Mr. Grauer will continue to serve as a director until the expiration of his current term at the 2020 Annual Meeting. He confirmed his departure is not due to any disagreement with the Company.
Guidance, Outlook, and Risks
The filing text does not contain specific forward-looking guidance, management commentary on future performance, or detailed risk factors beyond the standard legal disclaimers regarding the press release. The filing notes that the information in Item 2.02 is furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 and YTD 2019 financial figures (revenue, EPS, cash flow).
- Confirm the timeline for the 2020 Annual Meeting of Stockholders to verify the exact date of Mr. Grauer's departure.
- Assess the impact of the DaVita Medical Group sale (completed June 2019) on the reported financial results in the press release.
- Monitor for the appointment of a new lead independent director to replace Mr. Grauer.